List of Excipients in Branded Drug ASMANEX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme Corp	ASMANEX	mometasone furoate	0085-1341	ANHYDROUS LACTOSE
Physicians Total Care Inc	ASMANEX	mometasone furoate	54868-5547	ANHYDROUS LACTOSE
Organon LLC	ASMANEX	mometasone furoate	78206-114	ANHYDROUS LACTOSE
Merck Sharp & Dohme Corp	ASMANEX HFA	mometasone furoate	0085-4333	ALCOHOL

ASMANEX Excipient Strategy and Commercial Opportunities in Inhaled Mometasone

Last updated: October 27, 2026

ASMANEX is a prescription inhaled corticosteroid based on mometasone furoate. Its commercial platform has two distinct formulation strategies: ASMANEX TWISTHALER, a lactose-carrier dry-powder inhaler, and ASMANEX HFA, a propellant-based metered-dose inhaler containing hydrofluoroalkane, ethanol, and oleic acid. The main excipient opportunities are in lactose engineering, low-global-warming-potential propellant substitution, device compatibility, particle engineering, and differentiated combination products.

What formulations does ASMANEX use?

ASMANEX has used two inhalation technologies in the United States:

Product	Dosage form	Principal excipients	Device	Key commercial implication
ASMANEX TWISTHALER	Dry powder inhalation	Lactose monohydrate carrier containing trace milk proteins	Breath-actuated, multidose device	Low formulation complexity, but lactose and device performance create differentiation barriers
ASMANEX HFA	Metered-dose inhalation aerosol	HFA-227 propellant, ethanol, oleic acid	Pressurized metered-dose inhaler	Compatible with patients who cannot use lactose-containing DPIs; exposed to propellant-transition risk

ASMANEX TWISTHALER contains mometasone furoate blended with lactose. The lactose acts as a carrier, improving powder flow, metering, dispersion, and dose reproducibility. The U.S. label warns that the lactose contains trace amounts of milk proteins, creating a contraindication for patients with severe milk-protein hypersensitivity. (U.S. Food and Drug Administration [FDA], 2023a)

ASMANEX HFA uses HFA-227 as the propellant, ethanol as a cosolvent, and oleic acid as a formulation stabilizer or suspension aid. The formulation does not use lactose as a carrier and is not subject to the same milk-protein warning. (FDA, 2023b)

How does the ASMANEX excipient strategy work?

The two products use different methods to solve the same delivery problem: reproducibly depositing a microgram-scale dose of mometasone furoate in the lungs.

Lactose-carrier strategy in ASMANEX TWISTHALER

Mometasone furoate is a potent corticosteroid administered at low nominal doses. A pure-drug powder would be difficult to meter consistently in a multidose inhaler. Lactose provides bulk and improves powder handling.

The critical excipient variables are:

• Lactose particle-size distribution
• Fine-particle fraction
• Surface morphology
• Moisture content
• Crystallinity
• Carrier-drug adhesion
• Powder deagglomeration during inhalation
• Device resistance and airflow dependence

The formulation must balance two competing requirements. Drug particles must adhere strongly enough to remain uniformly distributed during storage and handling, but they must detach from the carrier during inhalation. Excessive adhesion reduces lung delivery. Weak adhesion can increase segregation and dose variability.

The lactose approach is commercially mature, but it remains difficult to copy precisely because performance depends on the interaction between excipient grade, micronized drug, blending process, capsule or reservoir geometry, and inhaler airflow.

HFA suspension strategy in ASMANEX HFA

ASMANEX HFA uses a suspension aerosol rather than a solution aerosol. Mometasone furoate is dispersed in the propellant system, with ethanol and oleic acid controlling suspension behavior and aerosol performance.

The formulation must control:

• Drug sedimentation and creaming
• Valve reproducibility
• Canister coating compatibility
• Spray plume geometry
• Priming and repriming performance
• Delivered-dose uniformity
• Fine-particle mass
• Chemical and physical stability

The HFA system creates a different development barrier from the dry powder product. A competitive manufacturer must match both the formulation and the metered-dose inhaler hardware. Small changes in valve, actuator, canister coating, or suspension rheology can alter lung deposition.

What are the FDA regulatory statuses of ASMANEX products?

ASMANEX is an FDA-approved prescription maintenance treatment for asthma. It is not a rescue inhaler and does not provide rapid relief of acute bronchospasm.

Product	FDA regulatory pathway	U.S. regulatory identifier
ASMANEX TWISTHALER	New drug application	NDA 021753
ASMANEX HFA	New drug application	NDA 205208

ASMANEX TWISTHALER was approved before ASMANEX HFA and established mometasone furoate as a maintenance inhaled corticosteroid. ASMANEX HFA expanded the product family into a pressurized aerosol platform. Both products require prescription dispensing and carry inhaled-corticosteroid warnings, including oral candidiasis, adrenal effects, hypersensitivity, and potential effects on growth in pediatric patients. (FDA, 2023a, 2023b)

Neither product is a biologic. Biosimilar regulation under the Public Health Service Act does not apply. Competitive products would generally proceed through the abbreviated new drug application pathway if they meet the relevant pharmaceutical-equivalence, bioequivalence, device, and performance requirements.

What excipients create the strongest commercial opportunities?

The largest opportunities are not generic commodity excipients alone. They are excipient-device systems that improve aerosol performance, regulatory acceptability, or patient segmentation.

1. Low-global-warming propellants

HFA-227 has a materially higher global-warming potential than newer propellant candidates. The pharmaceutical industry is evaluating HFA-152a and hydrofluoroolefin technologies for metered-dose inhalers. A reformulated mometasone aerosol using a lower-impact propellant could extend the commercial life of the product while addressing environmental procurement requirements.

The main development barriers are:

• New propellant safety packages
• Flammability assessment for HFA-152a
• Container and valve compatibility
• Reformulation stability
• Dose-delivery comparability
• Device redesign
• Clinical and human-factors bridging
• Manufacturing-site qualification

A lower-global-warming ASMANEX HFA could be positioned as a lifecycle-management product rather than a conventional generic. The strongest commercial model would combine a new formulation, proprietary valve or actuator, and a device transition program.

2. Lactose-free dry-powder systems

A lactose-free DPI would address patients with severe milk-protein allergy and reduce dependence on lactose carrier specifications. Potential alternatives include:

• Mannitol
• Trehalose
• Leucine
• Dextrose
• Spray-dried composite particles
• Engineered porous particles
• Excipient-free or near-excipient-free powders

The regulatory and technical challenge is that a substitute carrier must reproduce the aerodynamic and dose-uniformity performance of lactose without creating new stability or hygroscopicity problems. Mannitol and trehalose can offer useful powder properties, but each requires optimization for moisture uptake, crystallization, and drug detachment.

A lactose-free mometasone DPI could command a premium in a targeted patient segment, although the overall market would be smaller than the general asthma population.

3. Engineered particle technologies

Spray drying and controlled crystallization can produce particles with improved dispersibility and reduced dependence on carrier lactose. Particle engineering may support:

• Higher fine-particle fraction
• Lower inspiratory-flow dependence
• More consistent lung deposition
• Reduced oropharyngeal deposition
• Smaller inhaler dose
• More stable performance under humidity stress

These technologies can create stronger formulation IP than simple excipient substitution. Patent claims may cover particle morphology, composition, manufacturing conditions, inhaler configuration, or aerodynamic performance.

4. Device-compatible excipients

In inhaled products, the excipient cannot be evaluated separately from the device. Commercial value can arise from improving:

• Metering precision
• Low-dose repeatability
• Dose-counter accuracy
• Powder deagglomeration
• Flow resistance
• Priming behavior
• Patient feedback
• Humidity protection

A supplier that can provide a qualified excipient grade with device-specific performance data has a stronger position than a supplier offering a chemically equivalent but unqualified material.

What generic entry risks exist for ASMANEX?

Generic competition is more difficult for inhaled products than for oral tablets because equivalence depends on formulation, device, and aerodynamic performance.

Generic ASMANEX TWISTHALER risks

A competing DPI must address:

• Pharmaceutical equivalence to mometasone furoate
• Comparable delivered-dose uniformity
• Comparable aerodynamic particle-size distribution
• Device usability
• Consistent performance across flow rates
• Stability across temperature and humidity
• Patient handling and dose-counting behavior

The lactose carrier is not itself a strong exclusivity barrier because lactose is widely available. The barrier lies in the integrated formulation-device process and in demonstrating comparable performance.

Generic ASMANEX HFA risks

A competing aerosol must match:

• Mometasone concentration
• Propellant composition
• Suspension stability
• Valve and actuator behavior
• Spray characteristics
• Delivered dose
• Fine-particle mass
• Priming and repriming performance

The HFA product may be more difficult to copy than a conventional solution aerosol because suspension behavior is sensitive to multiple manufacturing variables.

When does ASMANEX lose exclusivity?

ASMANEX exclusivity has two separate components: regulatory exclusivity and patent protection.

FDA approval does not mean that all patents have expired. Conversely, the expiration of a listed patent does not automatically establish immediate generic market entry. Entry depends on the remaining Orange Book listings, Paragraph IV certifications, litigation, settlements, pediatric exclusivity, and the ability of a competing product to obtain approval.

The relevant FDA products are listed under NDA 021753 for ASMANEX TWISTHALER and NDA 205208 for ASMANEX HFA. Current patent expiration dates should be taken from the live Orange Book patent and exclusivity records rather than historical product literature. (FDA, n.d.-a)

Orange Book and Paragraph IV considerations

A generic applicant may file:

• Paragraph I certification, stating no patent information is listed
• Paragraph II certification, stating the patent has expired
• Paragraph III certification, accepting approval after patent expiration
• Paragraph IV certification, alleging that the patent is invalid, unenforceable, or not infringed

For an inhaled product, Paragraph IV risk can involve formulation claims, device claims, method-of-use claims, or manufacturing claims. A patent challenge does not guarantee commercial launch. Litigation can delay approval, settlement can establish a future launch date, and regulatory deficiencies can prevent approval even after patent disputes are resolved.

What patents protect ASMANEX formulations and devices?

The commercially relevant patent categories are likely to include:

Patent category	Subject matter	Relevance to excipient strategy
Composition patents	Mometasone furoate formulations	May cover excipient combinations or concentration ranges
Dry-powder formulation patents	Lactose-drug blends, particle size, dispersion	Directly relevant to TWISTHALER substitutes
Aerosol formulation patents	Propellant, ethanol, oleic acid, suspension properties	Relevant to ASMANEX HFA redesigns
Device patents	Inhaler geometry, metering, dose counter	Can block substitution even where formulation is equivalent
Manufacturing patents	Micronization, blending, filling, crimping, coating	May create process barriers
Method-of-use patents	Asthma maintenance treatment and dosing regimens	Can affect ANDA labeling and litigation strategy

Patent strength is highest where claims cover the integrated formulation-device system and where bioequivalence cannot be demonstrated through simple analytical testing. Broad claims to mometasone furoate alone are less likely to provide durable protection because the active ingredient is established and multiple delivery formats exist.

Which companies are challenging or competing with ASMANEX?

The competitive landscape includes three groups:

1. Generic manufacturers developing mometasone furoate DPIs or aerosols.
2. Branded inhaled corticosteroid manufacturers, including suppliers of fluticasone, budesonide, and beclomethasone products.
3. Combination-product manufacturers offering an inhaled corticosteroid with a long-acting beta agonist.

The most commercially important branded comparisons are:

Product	Active corticosteroid	Delivery strategy	Competitive distinction
ASMANEX	Mometasone furoate	DPI and HFA aerosol	Multiple device formats
FLOVENT	Fluticasone propionate or fluticasone furoate	DPI or aerosol	Strong class presence and combination-product competition
PULMICORT	Budesonide	DPI or nebulized suspension	Broad pediatric and nebulizer relevance
QVAR	Beclomethasone dipropionate	HFA aerosol	Established aerosol platform
ARNUITY ELLIPTA	Fluticasone furoate	DPI	Once-daily positioning

The primary commercial threat is not a single excipient substitute. It is the combination of generic mometasone, lower-cost inhaled corticosteroids, and combination products that improve adherence or simplify therapy.

What licensing deals and manufacturing opportunities exist?

Excipient and device companies can pursue several licensing models:

Reformulation licensing

A lower-global-warming propellant formulation could be licensed to a branded owner or regional manufacturer. The deal would likely include formulation know-how, stability data, valve specifications, and manufacturing transfer rights.

Platform licensing

A spray-dried particle platform could be licensed across multiple inhaled corticosteroids. This model is more attractive than a single-product license because the same particle-engineering process can support mometasone, budesonide, or fluticasone products.

Contract development and manufacturing

Opportunities exist for:

• Micronized mometasone blending
• DPI reservoir filling
• HFA suspension manufacture
• Canister filling and crimping
• Device assembly
• Stability and aerodynamic testing
• Combination-product human-factors work

Manufacturing IP is important because inhaled products require specialized containment, micronization, low-humidity handling, and aerosol-performance testing. A manufacturer with validated inhalation infrastructure can become a strategic partner even without owning core formulation patents.

How strong is the ASMANEX patent and excipient estate?

The estate is strongest in product-specific delivery barriers, not in basic excipient ownership.

The practical strength assessment is:

Area	Relative strength	Reason
Mometasone active ingredient	Low	Established corticosteroid
Lactose carrier	Low to moderate	Commodity excipient; performance depends on grade and process
TWISTHALER device	Moderate to high	Device replication and user-performance requirements
HFA suspension system	Moderate	Multiple interacting formulation and hardware variables
Low-global-warming reformulation	Potentially high	New composition, device, and process IP possible
Manufacturing process	Moderate	Specialized equipment and process controls may be difficult to replicate
Method of use	Variable	Scope depends on the specific listed claims and label

A competitor that replaces lactose, changes the propellant, or redesigns the device may avoid selected claims but face a fresh regulatory burden. A competitor that closely copies the existing product may simplify development but increase patent and trade-secret exposure.

What is the revenue exposure for ASMANEX?

ASMANEX revenue is not generally disclosed as a standalone line item in public financial reporting. Organon reports products within broader portfolio categories, which limits product-level revenue analysis. (Organon & Co., 2024)

Commercial exposure depends on:

• U.S. share of product sales
• Reimbursement tier placement
• Generic substitution
• Relative use of TWISTHALER versus HFA
• Prescriber preference for device type
• Availability of competing inhaled corticosteroids
• Patient ability to generate sufficient inspiratory flow
• Environmental procurement rules affecting HFA products

The most defensible commercial opportunity is therefore not a forecast of ASMANEX sales. It is a lifecycle strategy that preserves access to mometasone through a differentiated device or propellant platform.

What generic launch scenarios are most likely?

Three scenarios are commercially plausible:

Scenario 1: Conventional generic DPI

A generic manufacturer launches a lactose-based mometasone DPI after resolving Orange Book and device-equivalence issues. This is the most direct price-erosion scenario for TWISTHALER.

Scenario 2: Device-differentiated mometasone DPI

A competitor introduces a new inhaler with improved dose counting, lower flow resistance, or better humidity protection. The product may compete on adherence and usability rather than price alone.

Scenario 3: Reformulated HFA or next-generation aerosol

A lower-global-warming aerosol uses a new propellant and redesigned valve. This could create a new branded or authorized-generic lifecycle product with greater regulatory and formulation complexity.

Key Takeaways

• ASMANEX uses two distinct excipient systems: lactose monohydrate in TWISTHALER and HFA-227, ethanol, and oleic acid in ASMANEX HFA.
• The strongest commercial opportunities involve excipient-device integration rather than commodity excipient supply.
• Low-global-warming propellants are the most significant lifecycle-management opportunity for the HFA product.
• Lactose-free DPI systems could address severe milk-protein allergy and create targeted differentiation.
• Generic entry requires more than active-ingredient equivalence. Device performance, aerodynamic particle-size distribution, dose uniformity, and usability are central.
• ASMANEX has no biosimilar pathway because mometasone furoate is a small-molecule drug.
• Patent risk is concentrated in formulation-device combinations, manufacturing processes, and method-of-use claims.
• Product-level ASMANEX revenue is not separately disclosed in public Organon reporting.
• Manufacturing capabilities in micronization, low-humidity blending, aerosol filling, and inhaler assembly are meaningful competitive assets.

FAQs

Can lactose be removed from ASMANEX TWISTHALER without changing the device?

Not automatically. Removing lactose changes powder bulk density, flow, adhesion, deagglomeration, and dose metering. A lactose-free formulation would require new formulation and device-performance data.

Does ASMANEX HFA contain lactose or milk protein?

The HFA formulation uses HFA-227, ethanol, and oleic acid and does not use lactose as a carrier. ASMANEX TWISTHALER contains lactose with trace milk proteins. (FDA, 2023a, 2023b)

Is a low-GWP ASMANEX aerosol likely to be a generic or a new branded product?

It could follow either model. A formulation using the same active ingredient but a materially different propellant and device may require a new regulatory and patent strategy rather than a straightforward generic substitution.

Which excipient is most important to ASMANEX DPI performance?

Lactose is the principal carrier excipient, but performance depends on its interaction with micronized mometasone, blending conditions, humidity, and the TWISTHALER device.

Can an excipient supplier obtain patent protection around a mometasone inhaler?

Yes. Patentable subject matter may include engineered particles, excipient combinations, propellant systems, particle-size distributions, device interfaces, manufacturing processes, and performance-defined formulations. A patent covering only a conventional commodity excipient would generally provide weaker differentiation.

References

Food and Drug Administration. (n.d.-a). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/scripts/cder/ob/

Food and Drug Administration. (2023a). ASMANEX TWISTHALER prescribing information. U.S. Department of Health and Human Services.

Food and Drug Administration. (2023b). ASMANEX HFA prescribing information. U.S. Department of Health and Human Services.

Food and Drug Administration. (n.d.-b). Drugs@FDA: FDA-approved drugs. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/scripts/cder/daf/

Organon & Co. (2024). Annual report for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.